89 related articles for article (PubMed ID: 28108288)
21. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
23. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.
Dia VP; Pangloli P
J Cell Physiol; 2017 Feb; 232(2):391-401. PubMed ID: 27198989
[TBL] [Abstract][Full Text] [Related]
27. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
28. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
[TBL] [Abstract][Full Text] [Related]
30. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
[TBL] [Abstract][Full Text] [Related]
31. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
32. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
33. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
Yan H; Guo BY; Zhang S
Biochem Biophys Res Commun; 2016 Feb; 470(4):947-54. PubMed ID: 26826383
[TBL] [Abstract][Full Text] [Related]
34. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
[TBL] [Abstract][Full Text] [Related]
35. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression.
Wu H; Wang K; Liu W; Hao Q
Biochem Biophys Res Commun; 2014 Feb; 444(2):141-6. PubMed ID: 24434152
[TBL] [Abstract][Full Text] [Related]
36. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
[TBL] [Abstract][Full Text] [Related]
37. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
38. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
39. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase.
Li X; Wang G; Zhao J; Ding H; Cunningham C; Chen F; Flynn DC; Reed E; Li QQ
Cell Mol Life Sci; 2005 Apr; 62(7-8):894-904. PubMed ID: 15868412
[TBL] [Abstract][Full Text] [Related]
40. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Tai SK; Yang MH; Chang SY; Chang YC; Li WY; Tsai TL; Wang YF; Chu PY; Hsieh SL
Cancer Sci; 2011 Apr; 102(4):895-902. PubMed ID: 21219537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
